keyword
https://read.qxmd.com/read/38530432/chemotherapy-initiated-cysteine-rich-protein-61-decreases-acute-b-lymphoblastic-leukemia-chemosensitivity
#1
JOURNAL ARTICLE
Pengchong Shi, Zhen Lin, Yanfang Song, Zhaozhong Li, Menglu Zeng, Li Luo, Yingping Cao, Xianjin Zhu
PURPOSE: Chemoresistance is a major challenge for acute lymphoblastic leukemia (ALL) treatment. Cysteine-rich protein 61 (Cyr61) plays an important role in drug resistance modulation of tumor cells, and Cyr61 levels are increased in the bone marrow of patients with ALL and contribute to ALL cell survival. However, the effect of Cyr61 on B cell acute lymphoblastic leukemia (B-ALL) cell chemosensitivity and the regulatory mechanisms underlying Cyr61 production in bone marrow remain unknown...
March 26, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38508753/-use-of-crispr-cas9-with-homology-directed-repair-hdr-to-gene-edit-topoisomerase-ii%C3%AE-in-human-leukemia-k562-cells-generation-of-a-resistance-phenotype
#2
JOURNAL ARTICLE
Jessika Carvajal-Moreno, Xinyi Wang, Victor A Hernandez, Milon Mondal, Xinyu Zhao, Jack C Yalowich, Terry S Elton
DNA topoisomerase IIβ (TOP2β/180; 180 kDa) is a nuclear enzyme that regulates DNA topology by generation of short-lived DNA double-strand breaks primarily during transcription. TOP2β/180 can be a target for DNA damage-stabilizing anticancer drugs, whose efficacy is often limited by chemoresistance. Our laboratory previously demonstrated reduced levels of TOP2β/180 (and the paralog TOP2α/170) in an acquired etoposide-resistant K562 clonal cell line, K/VP.5 in part due to overexpression of microRNA-9-3p/5p impacting post-transcriptional events...
March 20, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38485947/histidine-re-sensitizes-pediatric-acute-lymphoblastic-leukemia-to-6-mercaptopurine-through-tetrahydrofolate-consumption-and-sirt5-mediated-desuccinylation
#3
JOURNAL ARTICLE
Na Dong, Hui-Xian Ma, Xue-Qin Liu, Dong Li, Ling-Hong Liu, Qing Shi, Xiu-Li Ju
Despite progressive improvements in the survival rate of pediatric B-cell lineage acute lymphoblastic leukemia (B-ALL), chemoresistance-induced disease progression and recurrence still occur with poor prognosis, thus highlighting the urgent need to eradicate drug resistance in B-ALL. The 6-mercaptopurine (6-MP) is the backbone of ALL combination chemotherapy, and resistance to it is crucially related to relapse. The present study couples chemoresistance in pediatric B-ALL with histidine metabolism deficiency...
March 14, 2024: Cell Death & Disease
https://read.qxmd.com/read/38468814/anlotinib-inhibits-cisplatin-resistance-in-non-small-cell-lung-cancer-cells-by-inhibiting-mcl-1-expression-via-met-stat3-akt-pathway
#4
JOURNAL ARTICLE
Lile Wang, Lu Xu, Shuhua Han, Xiaoli Zhu
BACKGROUND: Anlotinib is an effective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear. METHODS: Cell viability was assessed by the cell counting kit 8 assay. Cell proliferation, migration, and invasion were determined using the colony formation assay and transwell assay...
2024: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://read.qxmd.com/read/38435427/integrative-single-cell-expression-and-functional-studies-unravels-a-sensitization-to-cytarabine-based-chemotherapy-through-hif-pathway-inhibition-in-aml-leukemia-stem-cells
#5
JOURNAL ARTICLE
Talia Velasco-Hernandez, Juan L Trincado, Meritxell Vinyoles, Adria Closa, Alba Martínez-Moreno, Francisco Gutiérrez-Agüera, Oscar Molina, Virginia C Rodríguez-Cortez, Pau Ximeno-Parpal, Narcís Fernández-Fuentes, Paolo Petazzi, Sergi Beneyto-Calabuig, Lars Velten, Paola Romecin, Raquel Casquero, Fernando Abollo-Jiménez, Rafael D de la Guardia, Patricia Lorden, Alex Bataller, Hélène Lapillonne, Ronald W Stam, Susana Vives, Montserrat Torrebadell, Jose L Fuster, Clara Bueno, Jean-Emmanuel Sarry, Eduardo Eyras, Holger Heyn, Pablo Menéndez
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIFhigh and HIFlow specific AML subgroups (inv(16)/ t (8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups...
February 2024: HemaSphere
https://read.qxmd.com/read/38426621/targeting-mitochondrial-bioenergetics-by-combination-treatment-with-imatinib-and-dichloroacetate-in-human-erythroleukemic-k%C3%A2-562-and-colorectal-hct%C3%A2-116-cancer-cells
#6
JOURNAL ARTICLE
Maria G Kakafika, Areti A Lyta, George I Gavriilidis, Stefanos A Tsiftsoglou, Androulla N Miliotou, Ioannis S Pappas, Ioannis S Vizirianakis, Lefkothea C Papadopoulou, Asterios S Tsiftsoglou
Tumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN ( FXN ) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562)...
April 2024: International Journal of Oncology
https://read.qxmd.com/read/38424136/circfam193b-interaction-with-prmt6-regulates-aml-leukemia-stem-cells-chemoresistance-through-altering-the-oxidative-metabolism-and-lipid-peroxidation
#7
JOURNAL ARTICLE
Xinyu Yang, Jinting Liu, Wancheng Liu, Hanyang Wu, Yihong Wei, Xiaodong Guo, Hexiao Jia, Can Can, Dongmei Wang, Xiang Hu, Daoxin Ma
Most forms of chemotherapy for acute myeloid leukemia (AML) are often ineffective in eliminating leukemic stem cells (LSCs), as their underlying mechanisms remain unclear. Here, we have identified circFAM193B, which regulates the redox biology of LSCs and is associated with unfavorable outcomes in AML patients. In vitro and in vivo assays suggested that circFAM193B significantly inhibits LSCs chemotherapy resistance and AML progression. Knockdown circFAM193B enhances mitochondrial OXPHOS function and inhibits the accumulation of reactive oxygen species and lipid peroxidation mediated by chemotherapy, which protects AML cells from oxidative stress-induced cell death...
February 29, 2024: Leukemia
https://read.qxmd.com/read/38417135/mutant-u2af1-induced-mis-splicing-of-mrna-translation-genes-confers-resistance-to-chemotherapy-in-acute-myeloid-leukemia
#8
JOURNAL ARTICLE
Peng Jin, Xiaoling Wang, Qiqi Jin, Yi Zhang, Jie Shen, Ge Jiang, Hongming Zhu, Ming Zhao, Dan Wang, Zeyi Li, Yan Zhou, Wenzhu Li, Wei Zhang, Yabin Liu, Siyang Wang, Wen Jin, Yuncan Cao, Guangying Sheng, Fangyi Dong, Shishuang Wu, Xiaoyang Li, Zhen Jin, Mengke He, Xiaxin Liu, Luonan Chen, Yunxiang Zhang, Kankan Wang, Junmin Li
Patients with primary refractory acute myeloid leukemia (AML) have a dismal long-term prognosis. Elucidating the resistance mechanisms to induction chemotherapy could help identify strategies to improve AML patient outcomes. Herein, we retrospectively analyzed the multi-omics data of more than 1,500 AML cases and found that patients with spliceosome mutations had a higher risk of developing refractory disease. RNA splicing analysis revealed that the mis-spliced genes in refractory patients converged on translation-associated pathways, promoted mainly by U2AF1 mutations...
February 28, 2024: Cancer Research
https://read.qxmd.com/read/38373594/panobinostat-sensitizes-arac-resistant-aml-cells-to-the-combination-of-azacitidine-and-venetoclax
#9
JOURNAL ARTICLE
Jianlei Zhao, Shuangshuang Wu, Deying Wang, Holly Edwards, Jenna Thibodeau, Seongho Kim, Paul Stemmer, Guan Wang, Jingji Jin, Süreyya Savasan, Jeffrey W Taub, Yubin Ge
The majority of acute myeloid leukemia (AML) patients respond to intensive induction therapy, consisting of cytarabine (AraC) and an anthracycline, though more than half experience relapse. Relapsed/refractory (R/R) AML patients are difficult to treat, and their clinical outcomes remain dismal. Venetoclax (VEN) in combination with azacitidine (AZA) has provided a promising treatment option for R/R AML, though the overall survival (OS) could be improved (OS ranges from 4.3 to 9.1 months). Overexpression of c-Myc is associated with chemoresistance in AML...
February 17, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38360867/leukemic-cell-secreted-interleukin-9-suppresses-cytotoxic-t-cell-mediated-killing-in-chronic-lymphocytic-leukemia
#10
JOURNAL ARTICLE
Gioia Boncompagni, Vanessa Tatangelo, Ludovica Lopresti, Cristina Ulivieri, Nagaja Capitani, Carmela Tangredi, Francesca Finetti, Giuseppe Marotta, Federica Frezzato, Andrea Visentin, Sara Ciofini, Alessandro Gozzetti, Monica Bocchia, Diego Calzada-Fraile, Noa B Martin Cofreces, Livio Trentin, Laura Patrussi, Cosima T Baldari
The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance. Leukemic cells shape the TME into a pro-survival and immunosuppressive niche through contact-dependent and contact-independent interactions with the cellular components of the TME. Immune synapse (IS) formation is defective in CLL. Here we asked whether soluble factors released by CLL cells contribute to their protection from cytotoxic T cell (CTL)-mediated killing by interfering with this process...
February 15, 2024: Cell Death & Disease
https://read.qxmd.com/read/38352301/the-escrt-protein-chmp5-promotes-t-cell-leukemia-by-controlling-brd4-p300-dependent-transcription
#11
Katharine Umphred-Wilson, Shashikala Ratnayake, Qianzi Tang, Rui Wang, Ballachanda N Devaiah, Lan Zhou, Qingrong Chen, Daoud Meerzaman, Dinah S Singer, Stanley Adoro
UNLABELLED: Oncogene activity rewires cellular transcription, creating new transcription networks to which cancer cells become addicted, by mechanisms that are still poorly understood. Using human and mouse models of T cell acute lymphoblastic leukemia (T-ALL), we identify an essential nuclear role for CHMP5, a cytoplasmic endosomal sorting complex required for transport (ESCRT) protein, in establishing and maintaining the T-ALL transcriptional program. Nuclear CHMP5 promoted the T-ALL gene program by augmenting recruitment of the co-activator BRD4 by the histone acetyl transferase p300 selectively at enhancers and super-enhancers, an interaction that potentiated H3K27 acetylation at these regulatory enhancers...
January 31, 2024: bioRxiv
https://read.qxmd.com/read/38349260/calcrl-knockdown-suppresses-cancer-stemness-and-chemoresistance-in-acute-myeloid-leukemia-with-flt3-itd-and-dnm3ta-r882-double-mutations
#12
JOURNAL ARTICLE
Shanhao Tang, Huiling Zhu, Lixia Sheng, Qitian Mu, Yi Wang, Kaihong Xu, Miao Zhou, Zhijuan Xu, An Wu, Guifang Ouyang
Acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (FLT3-ITD) and DNA methyltransferase 3A (DNMT3A) R882 double mutations had a worse prognosis compared with AML with FLT3-ITD or DNMT3A R882 single mutation. This study was designed to explore the specific role of Calcitonin Receptor Like (CALCRL) in AML with FLT3-ITD and DNMT3A R882 double mutations. MOLM13 cells were transduced with CRISPR knockout sgRNA constructs to establish the FTL3-ITD and DNMT3A-R882 double-mutated AML cell model...
February 2024: Drug Development Research
https://read.qxmd.com/read/38296962/long-noncoding-rna-dleu2-and-ror1-pathway-induces-epithelial-to-mesenchymal-transition-and-cancer-stem-cells-in-breast-cancer
#13
JOURNAL ARTICLE
Syed S Islam, Taher Al-Tweigeri, Layla Al-Harbi, Shafat Ujjahan, Maha Al-Mozaini, Asma Tulbah, Abdelilah Aboussekhra
Breast cancer (BC) patient who receives chemotherapy for an extended length of time may experience profound repercussions in terms of metastases and clinical outcomes due to the involvement of the epithelial-to-mesenchymal transition (EMT) mechanism and enriched cancer stem cells (CSCs). BC cells that express high levels of lncRNA deleted in lymphocytic leukemia-2 (lncRNA DLEU2) and type I tyrosine kinase-like orphan receptor ROR1 (ROR1) may play roles in the enhanced ability of the activation EMT and CSC induction...
January 31, 2024: Cell Death Discovery
https://read.qxmd.com/read/38294636/glycolysis-modulation-by-mettl7b-shapes-acute-lymphoblastic-leukemia-cell-proliferation-and-chemotherapy-response
#14
JOURNAL ARTICLE
Li Zhang, Xiao Liu, Shuai Zhou, Peng Wang, Xuan Zhang
Acute lymphoblastic leukemia (ALL) is a devastating hematological malignancy characterized by uncontrolled proliferation of immature lymphoid cells. While advances in treatment have improved patient outcomes, challenges remain in enhancing therapeutic efficacy and understanding underlying molecular mechanisms. Methyltransferase-like 7B (METTL7B), known for its methyltransferase activity, has been implicated in various solid tumors, yet its role in ALL remains unexplored. Here, we reveal that high METTL7B expression is correlated with poorer prognosis in ALL patients...
January 31, 2024: Human Cell
https://read.qxmd.com/read/38268050/a-novel-aml1-eto-fto-positive-feedback-loop-promotes-leukemogenesis-and-ara-c-resistance-via-stabilizing-igfbp2-in-t-8-21-acute-myeloid-leukemia
#15
JOURNAL ARTICLE
Wei Zhou, Siying Li, Hong Wang, Jingfeng Zhou, Shuyi Li, Guofeng Chen, Wei Guan, Xianli Fu, Clara Nervi, Li Yu, Yonghui Li
BACKGROUND: t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subtype with a favorable prognosis, approximately 30-50% of patients experience drug resistance and subsequent relapse. N6 -methyladenosine (m6 A) is demonstrated to be involved in the development of AML. However, the regulatory mechanisms between AML1-ETO and m6 A-related enzymes and the roles of dysregulated m6 A modifications in the t(8;21)-leukemogenesis and chemoresistance remain elusive...
January 24, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38240344/dna-pkcs-mediated-transcriptional-regulation-of-top2%C3%AE-drives-chemoresistance-in-acute-myeloid-leukemia
#16
JOURNAL ARTICLE
Saket V Mishra, Archisman Banerjee, Debashmita Sarkar, Vishnuvarthan Thangarathnam, Bhausaheb Bagal, Syed K Hasan, Shilpee Dutt
Anthracyclines, topoisomerase 2 enzyme poison that results in DNA damage, are the mainstay of acute myeloid leukemia (AML) treatment. However, acquired resistance to anthracyclines leads to relapse, which currently lacks effective treatment and is the cause of poor survival in AML patients. Therefore, the identification of the mechanisms underlying anthracycline resistance remains an unmet clinical need. Here, using patient-derived primary cultures and clinically relevant cellular models that recapitulate acquired anthracycline resistance in AML, we found GCN5-mediated transcriptional upregulation of DNA-PKcs in AML relapse, independent of the DNA-damage response...
January 19, 2024: Journal of Cell Science
https://read.qxmd.com/read/38223131/clinicopathological-significance-and-expression-pattern-of-bcl2-in-breast-cancer-a-comprehensive-in-silico-and-in-vitro-study
#17
JOURNAL ARTICLE
Shazia Sofi, Umar Mehraj, Nusrat Jan, Abdullah Almilaibary, Irshad Ahmad, Fuzail Ahmad, Manzoor Ahmad Mir
B-cell lymphoma/leukemia gene-2 (Bcl-2) is the primary proto-oncogene that has been shown to work by preventing apoptosis/programmed cell death. Bcl-2 combines a variety of cell-generated signals associated to the survival and death of cells. In glioma, lung, and breast cancer, Bcl-2 over-expression has been linked to an increase in invasion and migration. Many treatment regimens that target Bcl2 have been established and approved, and thus increasing the survival rates of the patients. The primary goal of this research was to recognize new therapeutic compounds that target Bcl2 and assess Bcl2 expression pattern in BC patients...
February 2024: Saudi Journal of Biological Sciences
https://read.qxmd.com/read/38203816/ulk2-is-a-key-pro-autophagy-protein-that-contributes-to-the-high-chemoresistance-and-disease-relapse-in-flt3-mutated-acute-myeloid-leukemia
#18
JOURNAL ARTICLE
Justine Lai, Claire Yang, Chuquan Shang, Will Chen, Michael P Chu, Joseph Brandwein, Raymond Lai, Peng Wang
We recently demonstrated that a small subset of cells in FLT3-mutated acute myeloid leukemia (AML) cell lines exhibit SORE6 reporter activity and cancer stem-like features including chemoresistance. To study why SORE6+ cells are more chemoresistant than SORE6- cells, we hypothesized that these cells carry higher autophagy, a mechanism linked to chemoresistance. We found that cytarabine (Ara-C) induced a substantially higher protein level of LC3B-II in SORE6+ compared to SORE6- cells. Similar observations were made using a fluorescence signal-based autophagy assay...
January 4, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38203669/an-in-vitro-model-for-acute-myeloid-leukemia-relapse-using-the-sore6-reporter
#19
JOURNAL ARTICLE
Justine Lai, Chuquan Shang, Will Chen, Iyare Izevbaye, Michael P Chu, Irwindeep Sandhu, Joseph Brandwein, Raymond Lai, Peng Wang
Many patients diagnosed with acute myeloid leukemia (AML) relapse within two years of the initial remission. The biology of AML relapse is incompletely understood, although cancer stem-like (CSL) cells have been hypothesized to be important. To test this hypothesis, we employed SORE6, a reporter designed to detect the transcriptional activity of the embryonic stem cell proteins Oct4 and Sox2, to identify/purify CSL cells in two FLT3-mutated AML cell lines. Both cell lines contained ~10% of SORE6+ cells in the steady state...
December 29, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38201437/high-mitochondrial-protein-expression-as-a-potential-predictor-of-relapse-risk-in-acute-myeloid-leukemia-patients-with-the-monocytic-fab-subtypes-m4-and-m5
#20
JOURNAL ARTICLE
Frode Selheim, Elise Aasebø, Øystein Bruserud, Maria Hernandez-Valladares
AML is a highly aggressive and heterogeneous form of hematological cancer. Proteomics-based stratification of patients into more refined subgroups may contribute to a more precise characterization of the patient-derived AML cells. Here, we reanalyzed liquid chromatography-tandem mass spectrometry (LC-MS/MS) generated proteomic and phosphoproteomic data from 26 FAB-M4/M5 patients. The patients achieved complete hematological remission after induction therapy. Twelve of them later developed chemoresistant relapse (RELAPSE), and 14 patients were relapse-free (REL_FREE) long-term survivors...
December 19, 2023: Cancers
keyword
keyword
53849
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.